Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Intraclonal Heterogeneity Caused By Activation-Induced Cytidine Deaminase Is Not a Prognostic Biomarker in Untreated Advanced Stage Follicular Lymphoma: An Analysis of SWOG S0016

Richard Burack, MD PhD, Hongli Li, MS, Diana G Adlowitz, PhD, Janice M Spence, PhD, Michael L. Leblanc, PhD, Lisa M. Rimsza, MD, Rita M. Braziel, MD, Catherine M. Spier, MD, Mark S Kaminski, MD, John P. Leonard, MD, Richard I. Fisher, MD, Sonali M. Smith, MD, Jonathan W. Friedberg, MD

Blood (2019) 134 (Supplement_1): 2771.

https://doi.org/10.1182/blood-2019-121632

Published: 2019

Journal Articles

Subclonal Mutations of TP53 Are Common in Untreated Follicular Lymphoma and Mutation Status Is Predictive of PFS When CHOP Is Combined with 131-Iodine Tositumomab but Not with Rituximab: An Analysis of SWOG S0016

Richard Burack, MD PhD, Hongli Li, MS, Janice M Spence, PhD, Diana Adlowitz, Lisa M. Rimsza, MD, Rita M. Braziel, MD, Catherine M. Spier, MD, Mark S Kaminski, MD, John P. Leonard, MD, Richard I. Fisher, MD, Michael L. Leblanc, PhD, Sonali M. Smith, MD, Jonathan W. Friedberg, MD

Blood (2018) 132 (Supplement 1): 919.

https://doi.org/10.1182/blood-2018-99-111399

Published: 2018

Journal Articles

Alisertib-Induced Polyploidy and Senescence in DH/DP-DLBCL Is Abrogated By Synthetic Lethal Interactions with Ibrutinib and Rituximab

Shariful Islam, MS, Wenqing Qi, PhD, Carla Morales, B.S., Laurence Cooke, M.S., Manjari Pandey, MD, Catherine M. Spier, MD, Daruka Mahadevan, MD PhD

Blood (2016) 128 (22): 5397.

https://doi.org/10.1182/blood.V128.22.5397.5397

Published: 2016

Journal Articles

Continued Excellent Outcomes in Previously Untreated Follicular Lymphoma Patients after Treatment with CHOP Plus Rituximab or CHOP Plus (131) Iodine-Tositumomab - Long Term Follow-up of Phase III Randomized Study SWOG S0016

Mazyar Shadman, MD MPH, Hongli Li, PhD, Lisa Rimsza, MD, John P. Leonard, MD, Mark S Kaminski, MD, Rita M Braziel, MD, Catherine M. Spier, MD, Ajay K Gopal, MD, David G Maloney, MD PhD, Bruce Cheson, MD, Shaker Dakhil, MD FACP, Michael LeBlanc, PhD, Sonali M. Smith, MD, Richard I. Fisher, MD, Jonathan W. Friedberg, MD, Oliver Press, MD PhD

Blood (2016) 128 (22): 616.

https://doi.org/10.1182/blood.V128.22.616.616

Published: 2016

Journal Articles

Aurora Plus PI3K Inhibition Abrogates PD-L1 Induction in Peripheral T-Cell Non-Hodgkin Lymphoma

Daruka Mahadevan, MD PhD, Eric Vick, PhD, Bryan Huber, MD, Carla Morales, B.S., Laurence Cooke, M.S., Catherine M. Spier, MD, Wenqing Qi, PhD

Blood (2015) 126 (23): 1560.

https://doi.org/10.1182/blood.V126.23.1560.1560

Published: 2015

Journal Articles

Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313

Daniel O. Persky, Thomas P. Miller, Joseph M. Unger, Catherine M. Spier, Soham Puvvada, B. Dino Stea, Oliver W. Press, Louis S. Constine, Kevin P. Barton, Jonathan W. Friedberg, Michael LeBlanc, Richard I. Fisher

Blood (2015) 125 (2): 236–241.

https://doi.org/10.1182/blood-2014-06-584623

Published: 2015

Journal Articles

Novel Targeted Combination Therapies for Peripheral T-Cell Lymphoma

Daruka Mahadevan, MD PhD, Carla Morales, BS, Bryan D. Huber, MD, Mansoor Ul Haq, MD, Catherine M. Spier, MD, Laurence S. Cooke, MS, Wenqing Qi, PhD

Blood (2014) 124 (21): 4494.

https://doi.org/10.1182/blood.V124.21.4494.4494

Published: 2014

Journal Articles

Long Term Follow up of SWOG S0313: Ibritumomab Tiuxetan Consolidation after 3 Cycles of CHOP Plus Radiotherapy for High Risk Limited Stage Aggressive B-Cell Lymphoma

Daniel O Persky, MD, Thomas P. Miller, MD, Joseph M Unger, PhD, Catherine M. Spier, MD, Soham D. Puvvada, MD, B. Dino Stea, MDPhD, Oliver W. Press, MD PhD, Louis Constine, MD, Kevin Barton, MD, Michael LeBlanc, PhD, Sonali Smith, MD, Richard I. Fisher, MD, Jonathan W. Friedberg, MD

Blood (2014) 124 (21): 4414.

https://doi.org/10.1182/blood.V124.21.4414.4414

Published: 2014

Journal Articles

Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma

Blood (2014) 124 (8): 1259–1265.

https://doi.org/10.1182/blood-2014-04-570044

Published: 2014

Journal Articles

Addition of Rituximab to MLN8237 An Aurora A Kinase Inhibitor Plus Vincristine or Docetaxel Has Synergistic Anti-Tumor Activity In a Mouse Model of Aggressive B-Cell Non-Hodgkin's Lymphoma

Daruka Mahadevan, MD, PhD, Laurence Cooke, BS, Xiaobing Liu, BS, Daniel Oscar Persky, MD, Catherine M. Spier, MD, Thomas P. Miller, MD, Wenqing Qi, PhD

Blood (2010) 116 (21): 3933.

https://doi.org/10.1182/blood.V116.21.3933.3933

Published: 2010

Journal Articles

Genetic Polymorphisms In Oxidative Stress-Related Genes Correlated with Outcome Following Anthracycline-Based Therapy for Aggressive B-Cell Non-Hodgkin Lymphomas

Heather L. Tardif, Song Yao, PhD, Bryan H. Goldman, MS, Catherine M. Spier, MD, Michael L. LeBlanc, PhD, Lisa M. Rimsza, MD, Daniel O. Persky, MD, Thomas P. Miller, MD, Richard I Fisher, MD, Christine B. Ambrosone, PhD, Margaret M. Briehl, PhD

Blood (2010) 116 (21): 321.

https://doi.org/10.1182/blood.V116.21.321.321

Published: 2010

Journal Articles

Histologic Subtypes Do Not Confer Unique Outcomes in Early-Stage Lymphoma: Long-Term Follow-Up of SWOG 8736.

Catherine M. Spier, MD, Michael LeBlanc, PhD, Ellen M. Chase, BS, Richard I. Fisher, MD, Thomas P. Miller, MD

Blood (2004) 104 (11): 3263.

https://doi.org/10.1182/blood.V104.11.3263.3263

Published: 2004

Journal Articles

Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project

Lisa M. Rimsza, Robin A. Roberts, Thomas P. Miller, Joseph M. Unger, Michael LeBlanc, Rita M. Braziel, Dennis D. Weisenberger, Wing C. Chan, H. Konrad Muller-Hermelink, Elaine S. Jaffe, Randy D. Gascoyne, Elias Campo, Deborah A. Fuchs, Catherine M. Spier, Richard I. Fisher, Jan Delabie, Andreas Rosenwald, Louis M. Staudt, Thomas M. Grogan

Blood (2004) 103 (11): 4251–4258.

https://doi.org/10.1182/blood-2003-07-2365

Published: 2004

NARROW

Intraclonal Heterogeneity Caused By Activation-Induced Cytidine Deaminase Is Not a Prognostic Biomarker in Untreated Advanced Stage Follicular Lymphoma: An Analysis of SWOG S0016

Subclonal Mutations of TP53 Are Common in Untreated Follicular Lymphoma and Mutation Status Is Predictive of PFS When CHOP Is Combined with 131-Iodine Tositumomab but Not with Rituximab: An Analysis of SWOG S0016

Alisertib-Induced Polyploidy and Senescence in DH/DP-DLBCL Is Abrogated By Synthetic Lethal Interactions with Ibrutinib and Rituximab

Continued Excellent Outcomes in Previously Untreated Follicular Lymphoma Patients after Treatment with CHOP Plus Rituximab or CHOP Plus (131) Iodine-Tositumomab - Long Term Follow-up of Phase III Randomized Study SWOG S0016

Aurora Plus PI3K Inhibition Abrogates PD-L1 Induction in Peripheral T-Cell Non-Hodgkin Lymphoma

Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313

Novel Targeted Combination Therapies for Peripheral T-Cell Lymphoma

Long Term Follow up of SWOG S0313: Ibritumomab Tiuxetan Consolidation after 3 Cycles of CHOP Plus Radiotherapy for High Risk Limited Stage Aggressive B-Cell Lymphoma

Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma

Addition of Rituximab to MLN8237 An Aurora A Kinase Inhibitor Plus Vincristine or Docetaxel Has Synergistic Anti-Tumor Activity In a Mouse Model of Aggressive B-Cell Non-Hodgkin's Lymphoma

Genetic Polymorphisms In Oxidative Stress-Related Genes Correlated with Outcome Following Anthracycline-Based Therapy for Aggressive B-Cell Non-Hodgkin Lymphomas

Histologic Subtypes Do Not Confer Unique Outcomes in Early-Stage Lymphoma: Long-Term Follow-Up of SWOG 8736.

Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only